By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Data detailed on Biotechnology have been presented. According to news reporting originating in Memphis, Tennessee, by NewsRx journalists, research stated, "Genetically engineered mouse models (GEMMs) of human cancer are important for advancing our understanding of tumor initiation and progression as well as for testing novel therapeutics. Retinoblastoma is a childhood cancer of the developing retina that initiates with biallelic inactivation of the RB1 gene."
The news reporters obtained a quote from the research from St. Jude Children's Research Hospital, "GEMMs faithfully recapitulate the histopathology, molecular, cellular, morphometric, neuroanatomical and neurochemical features of human retinoblastoma. In this study, we analyzed the genomic and epigenomic landscape of murine retinoblastoma and compared them to human retinoblastomas to gain insight into shared mechanisms of tumor progression across species. Similar to human retinoblastoma, mouse tumors have low rates of single nucleotide variations. However, mouse retinoblastomas have higher rates of aneuploidy and regional and focal copy number changes that vary depending on the genetic lesions that initiate tumorigenesis in the developing murine retina. Furthermore, the epigenetic landscape in mouse retinoblastoma was significantly different from human tumors and some pathways that are candidates for molecular targeted therapy for human retinoblastoma such as SYK or MCL1 are not deregulated in GEMMs."
According to the news reporters, the research concluded: "Taken together, these data suggest there are important differences between mouse and human retinoblastomas with respect to the mechanism of tumor progression and those differences can have significant implications for translational research to test the efficacy of novel therapies for this devastating childhood cancer."
For more information on this research see: Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget, 2013;4(6):844-59 (see also technology.html">Biotechnology).
Our news correspondents report that additional information may be obtained by contacting C.A. Benavente, Dept. of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, United States. Additional authors for this research include J.D. McEvoy, D. Finkelstein, L. Wei, G. Kang, Y.D. Wang, G. Neale, S. Ragsdale, V. Valentine, A. Bahrami, J. Temirov, S. Pounds, J. Zhang and M.A Dyer.
Keywords for this news article include: Biotechnology, Memphis, Genetics, Oncology, Tennessee, Pediatrics, Therapeutics, United States, Eye Neoplasms, Ophthalmology, Retinoblastoma, Retinal Diseases, Retinal Neoplasms, Cancer Gene Therapy, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC